Biotech | April 04, 2025
Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Collaboration supports multiple discovery efforts, including vaccines
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Subscribe To Our Newsletter & Stay Updated
